IBT Ibex Technologies Inc

IBEX Technologies Inc. (TSX VENTURE:IBT), today reported its financial results
for the fourth quarter and year ended July 31, 2008.


Solely for the convenience of the reader, selected financial results expressed
in Canadian dollars on the financial statements, have been translated into U.S.
dollars at the July 31, 2008 month-end rate C$1.00 equal to US$ 0.9766. This
translation should not be construed as an application of the recommendations
relating to the accounting for foreign currency translation, but rather as
supplemental information for the reader.


2008 Company Highlights

- Reaches profitability sooner than targeted in first year of turn-around.

- Achieves record sales.

- Working capital increases 30.6%.

"I am pleased to report that the Company has exceeded its goals for Fiscal 2008
and is on a sound financial footing for the future. Both major product lines
grew significantly and we successfully reduced our base operating costs" said
Paul Baehr, IBEX President and CEO.


Financial Results for the Fiscal Year

Sales for the year ended July 31, 2008 totaled $2,326,744 (US$2,272,298)
compared to $2,023,624 for the same period in the prior year, representing an
increase of 15%.


Net profit for the year ended July 31, 2008 was $348,319 (US$340,168) or $0.01
per share compared to a net loss of $7,409,662 or ($0.32) per share for fiscal
2007.


The Company's net loss for fiscal 2007 was exacerbated by a write-down of
$3,816,924 in identifiable intangible assets, a write-down of $1,060,740 for a
loan receivable (attributable to an abandoned business combination), and by
severance expenses (following its restructuring plan in the fourth quarter of
fiscal 2007).


Cash and Working Capital

The Company's Cash, Cash Equivalents, and Marketable Securities improved 8% over
the year to $1,567,264.


The Company's working capital was $1,832,492 as at the end of the year (well
ahead of the Company's guidance at the time of the restructuring) and up from
$1,629,408 as at the end of the prior quarter ending April 30, 2008 and
$1,403,321 as at July 31, 2007.




Financial Summary for the Years Ending

                                           July 31, 2008   July 31, 2007

Revenues(i)                                   $2,326,744      $2,023,624

Earning Before Interests, Tax,
 Depreciation & Amortization                    $367,185     ($7,669,365)

Depreciation, Amortization & Write-Downs         $70,148      $5,014,779

Net Profit (Loss)                               $348,319     ($7,409,662)

Profit (Loss per Share)                            $0.01          ($0.32)

Cash, Cash Equivalents &
 Marketable Securities                        $1,567,264      $1,448,425

Working Capital                               $1,832,492      $1,403,321

Outstanding shares at report date
 (Common shares)                              24,703,244      24,703,244



(i) Revenues no longer include research tax credits, which are now treated as a
reduction in expense.


Results for the Quarter

Sales for the three-month period ended July 31, 2008 totaled $509,944
(US$498,011) compared to $569,512 in the fourth quarter of fiscal 2007,
representing a decrease of 10%. The sales for this quarter compare unfavorably
to both the prior quarter $712,997 and to year ago due to the very robust third
quarter which included an unusually large one-time order.


Net profit for the fourth quarter of fiscal 2008 was $189,697 (US$185,258) or
$0.01 per share, compared to a net loss of $5,508,725 or ($0.32) per share for
the same quarter in fiscal 2007. The Company's net loss for fiscal 2007 was
exacerbated by significant write downs (including $3,816,924 in identifiable
intangible assets and $1,060,740 for a loan receivable attributable to an
abandoned business combination), and severance expenses (following its
restructuring plan in the fourth quarter of fiscal 2007).


LOOKING FORWARD

IBEX has been successful in bringing its existing business to profitability and
is now turning its attention to pursuing growth opportunities, including further
growing its base business, and maximizing shareholder value through strategic
initiatives with companies where increased market strength and synergies might
be obtained.


ABOUT IBEX

The Company manufactures and markets a series of proprietary enzymes
(heparinases and chondroitinases) for use in pharmaceutical research by our
customers, as well Heparinase I, which is used in many leading hemostasis
monitoring devices.


IBEX also manufactures and markets a series of arthritis assays which are widely
used in pharmaceutical research by our customers. These assays are based on the
discovery and increasing role of a number of specific molecular biomarkers
associated with collagen synthesis and degradation.


For more information, please visit the Company's web site at www.ibex.ca.

Safe Harbor Statement

All of the statements contained in this news release, other than statements of
fact that are independently verifiable at the date hereof, are forward-looking
statements. Such statements, based as they are on the current expectations of
management, inherently involve numerous risks and uncertainties, known and
unknown. Some examples of known risks are: the impact of general economic
conditions, general conditions in the pharmaceutical industry, changes in the
regulatory environment in the jurisdictions in which IBEX does business, stock
market volatility, fluctuations in costs, and changes to the competitive
environment due to consolidation or otherwise. Consequently, actual future
results may differ materially from the anticipated results expressed in the
forward-looking statements. IBEX disclaims any intention or obligation to update
these statements.

Ibex Technologies (TSXV:IBT)
Historical Stock Chart
From Nov 2024 to Dec 2024

Ibex Technologies (TSXV:IBT)
Historical Stock Chart
From Dec 2023 to Dec 2024